Amicus Therapeutics Inc
F:AM6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amicus Therapeutics Inc
F:AM6
|
US |
|
P
|
Petchsrivichai Enterprise PCL
SET:PCE
|
TH |
|
T
|
TMT Steel PCL
SET:TMT
|
TH |
|
D
|
Dynasty Ceramic PCL
SET:DCC
|
TH |
|
T
|
Thai Packaging & Printing PCL
SET:TPP
|
TH |
Intrinsic Value
Is AM6 undervalued or overvalued?
See the intrinsic value estimate for Amicus Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
AM6 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with AM6’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Amicus Therapeutics Does
Amicus Therapeutics is a biotechnology company that develops and sells treatments for rare genetic diseases, especially lysosomal storage disorders. Its main medicines are for people with Fabry disease and Pompe disease, two serious inherited conditions that can damage organs and make everyday life difficult. The company works with doctors, specialty pharmacies, and health systems that treat these patients.
- Headquarters
- United States of America US
- Employees
- 496
- IPO date
- May 31, 2007
Revenue & Expenses Breakdown
Amicus Therapeutics Inc
Earnings Waterfall
Amicus Therapeutics Inc
The intrinsic value for Amicus Therapeutics Inc (AM6) under the Base Case is hidden EUR.
Compared with the current market price of 12.295 EUR, the stock appears hidden.